In the heart, acute injury induces a fibrotic healing response that generates collagen-rich scarring that is at first protective but if inappropriately sustained can worsen heart disease. The fibrotic process is initiated by cytokines, neuroendocrine effectors, and mechanical strain that promote resident fibroblast differentiation into contractile and extracellular matrix-producing myofibroblasts. The mitogen-activated protein kinase p38α (Mapk14 gene) is known to influence the cardiac injury response, but its direct role in orchestrating programmed fibroblast differentiation and fibrosis in vivo is unknown.
Fibroblast-Specific Genetic Manipulation of p38 Mitogen-Activated Protein Kinase In Vivo Reveals Its Central Regulatory Role in Fibrosis
T he ability to generate a fibrotic scar after myocardial infarction (MI) injury through the accumulation of extracellular matrix (ECM) is critical for acute wound healing, yet excessive fibrosis worsens disease and accelerates the progression to heart failure. [1] [2] [3] [4] [5] [6] The inability to directly treat fibrosis is due to an incomplete understanding of the underlying molecular regulatory pathways that directly program the process and the associated activation of tissue resident fibroblasts into myofibroblasts. This programmed conversion into myofibroblasts is associated with greater secretion of ECM and tissue remodeling because these cells likely become contractile as a result of newly acquired expression of genes such as smooth muscle α-actin (αSMA). 2, 7, 8 Injured tissues contain a variety of mechanical and cytokine/neurohumoral signals that contribute to the differentiation of fibroblasts into myofibroblasts, although effective pharmacotherapies based on these regulatory events have yet to emerge. 2, 6 Transforming growth factor-β (TGFβ) signaling directly mediates myofibroblast differentiation and ECM production, although much of this work was performed in vitro. 2 In fibroblasts, activation of TGFβ receptor 1-TGFβ receptor 2 heterodimers causes the transcription factors SMAD2/3 to complex with SMAD4 in the nucleus in altering gene expression to promote myofibroblast differentiation. 9 Studies in Smad3-null mice suggest its importance for injury-induced ECM secretion, although αSMA-positive myofibroblasts were still present, suggesting that multiple effectors are likely critical for the full fibrotic response downstream of TGFβ signaling. 10 Similarly, overexpression of inhibitory SMADS failed to block TGFβ-dependent αSMA stress fiber formation in isolated cardiac fibroblasts, again suggesting that additional pathways are required for full myofibroblast differentiation and function. 11 TGFβ receptor signaling can also initiate myofibroblast differentiation through a noncanonical pathway mediated by mitogen-activated protein kinase (MAPK) effectors such as MAPK kinase 6 (MKK6) and its direct downstream target kinase, p38. 2, 9 Activation of MKK6-p38 in fibroblasts and other mesenchymal cell types induces collagen and αSMA transcriptional activity, as well as the morphological appearance of αSMA-positive stress fibers. [11] [12] [13] Moreover, pharmacological inhibitors of p38 activity reduce fibrotic remodeling in skeletal muscle of muscular dystrophy models and more broadly in diseased hearts, lungs, and kidneys. 12, [14] [15] [16] [17] Using newly engineered tamoxifen-inducible Cre recombinase gene-targeted mice for genetic manipulation of either tissue resident fibroblasts or differentiated myofibroblasts, [18] [19] [20] [21] we show that Mapk14 (p38α) deletion blocks myofibroblast formation in vivo in multiple tissues and in response to various disease-causing stimuli. Moreover, induction of p38 activity by transgenesis with an activated MKK6 cDNA in fibroblasts was sufficient to drive fibrosis and myofibroblast formation in multiple tissues of the mouse.
METHODS

Animal Models
LoxP-targeted Mapk14 mice and mice containing a knockin of a MerCreMer (MCM) cDNA into either the Tcf21 or Postn genomic loci were previously described (C57BL/6 background). 17, 18, 20, 22 Constitutively active MKK6 transgenic (Tg) mice (C57BL/6 background) were engineered with a cytomegalovirus-β-actin (chicken β-actin) promoter construct 23 in which an activated human MKK6 cDNA was cloned downstream of a LoxP-flanked chloramphenicol acetyl transferase-polyA stop sequence. Tamoxifen was given by intraperitoneal injection in control and experimental mice with pharmaceutical-grade tamoxifen dissolved in peanut oil for 5 consecutive days (100 mg/kg body weight), followed by maintenance on tamoxifen-citrate chow (400 mg/kg body weight, Harlan Laboratories) for a minimum of 2 weeks or until the experiment was terminated.
MI injury was generated by permanently ligating the left coronary artery of ≈8-week-old mice. 24, 25 To model ischemia/ reperfusion (I/R) injury, the left coronary artery was transiently
Clinical Perspective
What Is New?
• This was one of the first studies to directly target a gene and associated signaling pathway within the fibroblast of a mammalian heart (mouse) and to show a direct role in regulating wound healing after myocardial infarction and effects on cardiac fibrosis.
• This study showed that the gene encoding p38α mitogen-activated protein kinase is required to mediate fibroblast activation in the mouse heart after injury and that forced activation of p38 within fibroblasts using a transgenic approach was sufficient to drive fibrosis in multiple tissues of the mouse, including the heart.
What Are the Clinical Implications?
• This study suggests that p38 mitogen-activated protein kinase is a nodal signaling effector within the cardiac fibroblast that drives wound healing and long-term fibrosis in heart failure.
• This study also suggests that pharmacological inhibition of p38 mitogen-activated protein kinase in human patients with heart failure could reduce progressive fibrotic burden and help maintain cardiac ventricular performance as a novel treatment.
• However, this study also suggests that pharmacological inhibition of p38 mitogen-activated protein kinase during acute myocardial infarction injury would inhibit wound healing and be detrimental to patients.
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ORIGINAL RESEARCH ARTICLE ligated for 30 minutes, followed by continuous reperfusion until the mice were euthanized and hearts harvested. For both MI and I/R surgical procedures, mice were perioperatively given a single subcutaneous injection of a mixture of lidocaine (1-4 mg/kg body weight) and bupivacaine (1-2 mg/kg body weight) at the site of surgical incision and anesthetized with inhaled 2% isoflurane, intubated through the mouth, and ventilated throughout the procedure. A single postoperative dosage of buprenorphrine sustained-release formula (3.25 mg/kg body weight) was given by subcutaneous injection at 0.05 to 0.1 mg/kg, as well as for all subsequent surgical procedures described below. M-mode echocardiography with a Hewlett Packard SONOS 5500 instrument was used to assess ventricular geometry and function 10 and 28 days after surgery in mice anesthetized with inhaled 2% isoflurane for the duration of the procedure. Because this is a noninvasive procedure, analgesia is not needed. Constant angiotensin II/phenylephrine (AngII/PE) treatment (432 μg·kg ) was delivered for 2 weeks by Alzet osmotic mini-pumps (Durect Corp), which were subcutaneously implanted in 8-week-old mice under inhaled 2% isoflurane anesthesia. For AngII/PE treatment, cardiac function and tissue collection were performed 14 days after treatment. At the completion of all studies, hearts were perfused in cardioplegic buffer to preserve diastolic dimensions and then fixed in 10% formalin, embedded in paraffin, and prepared for histological analysis. Fibrosis was assessed by Masson trichrome staining at 10 and 28 days after I/R injury, 14 days after AngII/PE treatment, or 4 months after MKK6 transgene induction (mice were then 5 months old). The average area of fibrosis was calculated across 5 evenly distributed transverse sections of the heart running from the apex to the base with National Institutes of Health Image J software.
For dermal wound healing assays, fully anesthetized 12-week-old mice (induced and maintained on inhaled 2% isoflurane) were given 2 dorsal 6-mm skin excision punch biopsies, and wound closure rate and health were assessed daily for 1 week as previously described. 11 Wound closure was calculated by measuring the change in wound area from the initial size of the biopsy. All animal experimentation was approved by the Institutional Animal Care and Use Committee of Cincinnati Children's Hospital Medical Center and the University of Washington. Number of mice used is given in the Results section and figure legends or shown in the figures.
Fibroblast Cultures and Treatments
Mouse embryonic fibroblasts (MEFs) were isolated from embryonic day 13.5 Mapk14 fl/fl mice for primary culture as described previously. 26 MEFs were cultured in DMEM supplemented with 10% FBS and nonessential amino acids, and passages 2 and 3 were used for experimentation. Myofibroblast differentiation was scored by αSMA stress fiber formation with immunocytochemistry 72 hours after induction with recombinant porcine TGFβ (10 ng/mL, R&D Systems), AngII (100 nmol/L, Sigma), or adenovirus delivering the following genes: activated calcineurin truncation, β-galactosidase (βgal), Cre recombinase, transient receptor potential canonical 6 (TRPC6), or serum response factor (SRF). 11, 24, 27, 28 These treatments were also used for collagen contraction assays. Here, 40 000 MEFs were seeded into collagen gel matrices and induced to differentiate, and gel area was measured 48 hours later. Stretch-induced differentiation was performed by seeding MEFs on 6-well Flexcell culture plates and imparting a 20% stretch to the membranes by loading the plates on large-diameter circular posts (28 mm, Flexcell International). Stretch oscillations were performed continuously for 48 hours at 2 different frequencies, 0.5 and 1.0 Hz, and then fixed for immunofluorescence staining.
Immunofluorescence, Flow Cytometry, and Western Blot Analysis
Cultured MEFs were fixed in 4% paraformaldehyde and stained with αSMA antibody (1:1000, mouse monoclonal, clone 1A4, Sigma) to detect actin stress fibers and DAPI (1:1000, Invitrogen) to visualize the nucleus. Alexa 488 or Alexa 568 conjugated secondary antibody directed against mouse IgG was used to detect αSMA. In cardiac tissue sections, myofibroblasts were identified in infarcted hearts 28 days after injury and in MKK6-Tg mice 4 months after tamoxifen induction. Hearts were dissected, fixed overnight in 10% formalin, and paraffin embedded. Sections (5 μm) were subjected to antigen retrieval and subsequently stained with the combination of αSMA antibody and isolectin-B4 (Vector Biolabs) for endothelial cell identification or for vimentin (1:250, rabbit monoclonal, Abcam).
For Western blotting of purified cardiac fibroblasts isolated from genetically modified hearts, a Langendorff apparatus was used to perfuse the heart with type II collagenase (2 mg/ mL) and liberase blendzyme (0.4 mg/mL) in Krebs-Henseleit buffer. Hearts were processed, and cells were collected and prepared for flow cytometry as described previously. 29 Cells were incubated for 1 hour with the fibroblast allophycocyaninconjugated antibody MEFSK4 (1:10, Miltenyi Biotec), washed 3 times in blocking buffer, and incubated with DAPI to identify live cells. The isolated fibroblast fraction was lysed in radioimmunoprecipitation assay buffer (Thermo Fisher Scientific) and prepared in Laemmli buffer (Sigma Aldrich) for SDS-PAGE and Western blotting. For each group, protein extract from 125 000 fibroblasts was loaded per lane, and the following antibodies were used: total p38α (1:1000, rabbit polyclonal, Cell Signaling), phosphorylated p38 (1:1000, rabbit polyclonal, Cell Signaling), MKK6 (1:500, rabbit polyclonal, Genetex), phosphorylated MAPKAP2 (MK2; 1:100, rabbit polyclonal, Cell Signaling), αSMA (1:1000, mouse monoclonal, Sigma), vimentin (1:1000, rabbit monoclonal, Abcam), and GAPDH (1:10 000, mouse monoclonal, Fitzgerald Industries).
Reverse Transcriptase-Polymerase Chain Reaction
Cardiac fibroblasts were isolated as described above, and RNA was isolated with Qiashredder homogenization and RNAeasy preparations (Qiagen). Total RNA was reverse transcribed with random hexamer primers and Superscript III first-strand synthesis kit (Invitrogen). Real-time polymerase chain reaction was performed with SsoAdvanced SYBR Green (Biorad), and GAPDH expression was used for normalization. The following primer sets were used to identify the human MKK6-Tg transcripts: 5'-CACTTGACCGAGAGCATTGATGAG and 5'-AGTCGAAAGGCAAGAAGCGA (Table I in the onlineonly Data Supplement).
Statistics
One-way ANOVA was used to determine statistical significance for experiments with >2 groups, and statistically significant pairwise differences were further determined by the Newman-Keuls methods (Prism software). For experiments in which 2 groups were compared, unpaired t tests were used to determine statistical significance. For survival assessments from the Kaplan-Meier curves, post hoc t tests were performed at each time point between Mapk14 fl/fl and Mapk14 fl/ fl Tcf21 MCM genotypes. Values of P<0.05 were considered statistically significant, and all the tests were performed 2 sided. To determine sample sizes for the proposed experiments, the desired power was established as 80% and the criterion for significance (α) is 0.05, which was n=8 to 12 for both MI and I/R injury and n=5 to 8 AngII/PE models.
RESULTS
Fibrotic Signals Require p38 MAPK for Myofibroblast Differentiation
Here, primary MEFs were first isolated from homozygous LoxP-targeted Mapk14 mice (Mapk14
fl/fl
) and then adenovirally transduced with either βgal (Adβgal) as a control or Cre recombinase (AdCre) to delete Mapk14. Four days after adenoviral transduction, p38α protein expression was reduced by >90% as detected by Western blot ( Figure 1A ). With the use of these conditions, MEFs with and without p38α were treated with TGFβ or AngII to differentiate them into αSMA-expressing myofibroblasts by immunocytochemistry ( Figure 1B) . We also measured mRNA levels for αSMA (Acta2), collagen 1a1, fibronectin, and EDA splice variant of fibronectin (Figure IA-ID and Table I in the online-only Data Supplement). Approximately 60% of wild-type MEFs differentiated into myofibroblasts 4 days after treatment with TGFβ or AngII, whereas Mapk14 fl/fl MEFs infected with AdCre failed to appreciably differentiate with these same 2 agonists ( Figure 1B) .
Our past studies showed that p38 directly stimulates SRF-mediated transcription of the TRPC6 channel that in turn activates Ca
2+
-calcineurin signaling, a pathway necessary for myofibroblast formation. 11 To confirm the placement of p38 in this pathway, control MEFs (Map- ORIGINAL RESEARCH ARTICLE ment). All 3 treatments elicited increased matrix gene expression and robust formation of αSMA expression and stress fibers in a majority of the fibroblast population independent of the presence of p38, suggesting that p38 lies upstream of these genetic inducers of myofibroblast differentiation ( Figure 1B and Figure IA through ID in the online-only Data Supplement).
We next used a collagen-gel contraction assay because the ability to contract is another signature of myofibroblasts ( Figure 1C and 1D ). Gels seeded with control MEFs replete with p38α (Mapk14 fl/fl , Adβgal) contracted when treated with TGFβ or AngII, but loss of p38α protein (Mapk14 fl/fl , AdCre) inhibited contraction ( Figure 1C and 1D) . However, proliferation rates in these same cells groups measured with 10 μmol/L 5-ethynyl-2'-deoxyuridine were not different in low serum but were slightly higher in the p38α-deleted cells with high serum, collectively indicating that the observed inhibition of gel contraction was not due to diminished fibroblast numbers during the assay period ( Figure IE in the online-only Data Supplement). Interestingly, none of the chemical inducers of myofibroblast differentiation used here converted 100% of the MEFs in culture, likely because of the heterogeneity in cell cycle and their phases of maturation during the differentiation process.
Mechanical rigidity and strain also trigger mesenchymal cells to undergo a change in fate. 2, 30 Here, Mapk-14 fl/fl control and deleted MEFs were cultured on silicon membranes and subjected to 40 hours of cyclic stretching with 20% strain (Figure 1E the population of wild-type MEFs to develop αSMA-positive stress fibers, whereas MEFs devoid of p38α showed significantly reduced levels ( Figure 1E and 1F) . These results indicate that p38α is also required for transducing mechanical signals underlying myofibroblast differentiation.
Deletion of Mapk14 in Resident Fibroblasts Minimizes Injury-Induced Cardiac Fibrosis
The in vitro work described above suggests that fibroblast-specific inhibition of p38α signaling blocks stimulus-induced myofibroblast formation. Indeed, 4 days after ischemic injury, p38α and p38γ gene expression increased specifically in cardiac fibroblasts ( Figure IIA and IIB in the online-only Data Supplement), although p38α was the dominant isoform identified. Hence, we deleted the Mapk14 gene encoding p38α only in resident fibroblasts using a tamoxifen-inducible MCM cDNA expressed from the Tcf21 genetic locus 18, 19 to examine cardiac injury responses and fibrosis in adult mice. Here, tamoxifen was given until the completion of the experiment at 3 months of age (Figure 2A ). Purified cardiac fibroblasts showed a 74% deletion of p38α protein as assessed by Western blotting ( Figure 2B ). Fibroblasts were flow-sorted with the MEFSK4 antibody, which is a global fibroblast marker that selects nearly 95% of Tcf21 + fibroblasts, although it can also detect CD11b + leukocytes. 29 To examine whether adult cardiac fibroblasts also require p38α to differentiate into myofibroblasts, the above-described flow cytometry method was used to isolate and culture cardiac fibroblasts from tamoxifentreated Using the same tamoxifen dosing strategy (Figure 2A) , we subjected Mapk14 fl/fl Tcf21 MCM mice and the proper controls to an I/R procedure because the standard MI injury protocol caused 100% lethality (data not shown). The I/R procedure was better tolerated by Mapk14 fl/fl Tcf21 MCM mice, which now showed only 50% left ventricular wall rupture versus 100% with MI injury (Figure 2C ). Despite this improved tolerance, Mapk14 fl/fl Tcf21 MCM mice still showed significantly greater lethality compared with I/R-injured littermate controls ( Figure 2C) . Inspection of the mice after I/Rinduced lethality showed ventricular wall rupture and inefficient fibrotic scar formation, as observed in other mouse models lacking proper fibrotic matrix deposition. 11 (Figure 2D and 2E) . Cardiac sections were also quantified for myofibroblast numbers by scoring for αSMA-positive and isolectin-B4-negative (endothelial marker) cells. The data show that although the border zone of hearts from I/R-injured Mapk14 fl/fl and Tcf21 MCM control mice had relatively large numbers of myofibroblasts, the same regions from hearts of Tcf21 MCM mice had lower isovolumetric relaxation times and E/e' ratios, suggesting that decreasing fibrosis abrogates injured-induced diastolic dysfunction (Table) .
Mapk14 Deletion in Existing Myofibroblasts Partially Reduces Cardiac Fibrosis
The Tcf21 MCM allele allows the deletion of Mapk14 from only resident fibroblasts in the heart, which permits assessment of the role of this signaling effector before an activating stimulus. However, we also assessed the importance of Mapk14 activity in maintaining myofibroblast function and differentiation during an injury event using a mouse model in which the MCM cDNA was ex- 
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pressed from the genetic locus of periostin (Postn). We have shown that Postn MCM mice can be used to mark essentially all newly activated fibroblasts (myofibroblasts) within the heart during an injury event, but not in unactivated fibroblasts. 20, 21 Here, tamoxifen was given to 8-week-old mice 5 days before MI surgery, and these mice were kept on tamoxifen until harvest 28 days later ( Figure 3A) . Separate cohorts of mice were also generated so that the Rosa26 mT/mG reporter allele could be used to track and isolate newly generated myofibroblasts. The data showed a 66% reduction in p38α protein with this cell sorting approach and a nearly complete loss of phospho-p38 signal by Western blotting (data not shown) Figure 3D and 3E) . Immunofluorescent staining indicated that myofibroblast number was also significantly reduced in hearts of injured groups ( Figure 3G-3I (Table) , suggesting that the remaining fibrotic area is still enough to trigger diastolic dysfunction. Overall, these results indicate that p38α is necessary for both generation of myofibroblasts with injury and their persistence (see discussion).
Here, we also modeled a more chronic fibrotic injury response by continuous infusion of AngII with PE as previously described. 21 Mapk14 fl/fl Postn MCM mice and their controls were subjected to 2 weeks of AngII/PE infusion via osmotic mini-pumps, which significantly increased cardiac ventricular mass and fibrosis in Mapk14 fl/fl and Postn MCM control mice ( Figure 4A-4C) . In comparison, myofibroblast-specific loss of Mapk14 blocked the hypertrophic response and significantly reduced cardiac fibrosis ( Figure 4A-4C ). Echocardiographic assessment revealed that left ventricular chamber dimensions and function were similar across all groups with 2 weeks of AngII/PE treatment ( Figure 4D and 4E) . However, the results show that p38α signaling is required in myofibroblasts to maintain the fibrotic function of these cells in response to AngII/PE neuroendocrine signaling, which also supports the hypertrophic response of the heart.
Fibroblast-Specific Activation of p38 Signaling Induces Fibrosis In Vivo
To determine whether activation of p38 MAPK signaling in fibroblasts is sufficient to drive myofibroblast differentiation in vivo, an inducible Cre-dependent system was used to express constitutively active MKK6 in Tg mice ( Figure 5A ). Real-time polymerase chain reaction of this MKK6 cDNA in cardiac fibroblasts isolated from MKK6-Tg mice and infected with AdCre showed that transgene expression is Cre dependent ( Figure 5B ). Similarly, dermal and pulmonary fibroblasts isolated from these Tg mice remained quiescence in culture without significant αSMA expression, yet AdCre infection induced de novo αSMA expression, stress fibers, and myofibroblast differentiation as MKK6 was expressed ( Figure 5C ). To assess the ability of activated MKK6 to induce fibrosis in vivo, we crossed mice containing the MKK6-Tg with Tcf21 MCM mice, and tamoxifen was given at weaning until 5 months of age when the experiment was terminated ( Figure 5A ). After this treatment protocol, the hearts of MKK6-Tg, Tcf21 MCM mice had significant accumulation of interstitial and perivascular fibrosis not observed in tamoxifen-fed controls ( Figure 5D and 5E). Moreover, other organs and known sites of Tcf21 expression such as the kidney and lung were also fibrotic in these mice, a result again not seen in non-Tg littermate controls given only tamoxifen ( Figure 5E ). Indexes of diastolic dysfunction were also examined by pulsewave and tissue Doppler imaging. MKK6-Tg, Tcf21 MCM mice had significantly higher isovolumetric relaxation times and E/e' relative to their non-Tg littermates and a level of diastolic dysfunction similar to that observed in I/R-injured Mapk14 fl/fl controls (Table) . Cardiac histological sections were also examined for myofibroblasts by immunofluorescent staining, which showed widespread staining in interstitial spaces, within the endocardium, near the epicardial borders, and in perivascular niches with MKK6-Tg expression ( Figure 5F ). In support of these data, fibroblasts purified from MKK6-Tg, Tcf21 MCM hearts using the MEFSK4 antibody showed high levels of myofibroblast markers such as αSMA and vimentin compared with isolated fibroblasts from Tcf21 MCM -only hearts, suggesting that p38 activation promoted ex- ORIGINAL RESEARCH ARTICLE pansion of cardiac fibroblasts and their conversion to myofibroblasts ( Figure 5G ). We also observed increased MKK6 protein expression in these purified fibroblasts from the hearts of MKK6-Tg, Tcf21 MCM mice, as well as activation of p38 and MK2, with phospho-specific antibodies and Western blotting ( Figure 5G ). These results indicate that increased p38 signaling in tissue-resident fibroblasts induces de novo myofibroblast formation and tissue fibrosis in otherwise healthy organs.
We also examined MKK6-Tg Postn MCM mice subjected to I/R injury in which tamoxifen was given as shown in Figure 3A . The mice were then examined 1 month after I/R injury by echocardiography and by histological and morphological assessments ( Figure 6A-6C) . We observed that cardiac mass and fibrotic area were significantly increased in MKK6-Tg, Postn MCM mice compared with control littermates (Figure 6B and 6C) but that cardiac function was not different between the groups ( Figure 6C) . Similarly, fibrotic injury induced by 2 weeks of AngII/PE infusion significantly elevated cardiac mass and fibrosis in the hearts of MKK6-Tg, Postn MCM mice compared with littermate controls (Figure 6D and 6E). There was also a nonsignificant trend toward reduced ventricular performance with AngII/PE infusion in MKK6-Tg, Postn MCM mice compared with control mice ( Figure 6F ). Taken together, these data suggest that MKK6-p38 signaling enhances the fibrotic response through priming and accentuating myofibroblast function during injury, which can also enhance the hypertrophic response of the heart.
We also examined whether MKK6-p38 signaling affects the fibrotic response in other conditions and tissues. In vitro wound closure rates were first assessed by creating microscale circular cutout wounds in mono- (Figure 7A) . To extend this in vitro assay, we also directly assessed wound healing in a skin model of injury. Here, MKK6-Tg, Postn MCM and Mapk14 fl/fl Postn MCM mice, along with their appropriate controls, were subjected to dermal punch biopsies and monitored for the rate of skin wound closure as previously described. 11, 21 Similar to the results obtained with cardiac injury, mice devoid of p38 signaling in their myofibroblasts (Mapk14 fl/fl Postn MCM ) had significantly slower wound closure rates relative to controls, whereas MKK6-Tg, Postn MCM mice had significantly faster rates of skin wound closure (Figure 7B and 7C) . These results again support the hypothesis that p38 signaling is both necessary and sufficient for myofibroblast-mediated tissue wound closure (healing), scar formation, and tissue fibrosis in vivo.
DISCUSSION
Our results show that inductive mechanical and paracrine signals converge on p38 to initiate programmed fibroblast to myofibroblast differentiation and the fibrotic response within the mouse heart. Indeed, genetic activation of p38 signaling in what would otherwise be called quiescent fibroblasts produced both αSMA-positive myofibroblasts and fulminant interstitial and perivascular fibrosis in the absence of an injury signal. Our results also demonstrate that genetic deletion of Mapk14 markedly inhibited the fibrotic response to ischemic injury, chronic neurohumoral stimulation, and skin wound closure, further indicating its necessity as a mediator of myofibroblast formation and tissue fibrosis in vivo, which also affects the cardiac hypertrophic response.
The high cardiac rupture rates observed in Mapk14 fl/fl-
Tcf21
MCM mice after MI or I/R injury demonstrate how vital both p38 signaling and myofibroblast function are to the structural integrity of the myocardium. Indeed, cardiac ventricular wall rupture has been associated with poor scar formation resulting from inefficient or incomplete ECM protein production or lack of myofibroblast formation in other mouse models. 11, 21, 25, [31] [32] [33] Similarly, mice carrying a diphtheria toxin gene that is turned on in myofibroblasts also had reduced scarring and poor survival after MI. 20, 34 There may also be intermediate stages of myofibroblast differentiation. For example, large amounts of fibrotic matrix can be secreted from less mature activated fibroblasts in which focal adhesions are immature and actin stress fibers contain cytoplasmic β-actin rather than αSMA. 35 Nonetheless, these immature myofibroblasts still contribute to fibrotic scarring. There may also be less fulminant injury states in which regions of myocardium lack the full range of neurohumoral and mechanical signals needed to induce αSMA-positive myofibroblasts. [35] [36] [37] Another interesting previous observation is that p38 is mechanically sensitive and that inhibition of p38 activity blocked aspects of stretch-induced myofibroblast differentiation 38 ( Figure 1F ). Last, we observed in vitro that differentiating fibroblasts had increased gene expression of ORIGINAL RESEARCH ARTICLE matrix proteins, including the EDA splice variant of fibronectin, which is uniquely secreted by myofibroblasts, 35 despite the fact that <100% of the fibroblast population show αSMA stress fibers when treated with a profibrotic agonist ( Figure 1B Previous in vitro experiments in MEFs and other mesenchymal cells have shown that inhibition of p38 signaling, including downstream effectors such as MK2, block the expression of myofibroblast signature proteins, with the reciprocal result observed when upstream p38 activators such as MKK6 and MKK3 are overexpressed. 11, 13, [38] [39] [40] Cultured fibroblasts treated with AngII showed that p38 activation was necessary for fibrosis, whereas TGFβ prolonged p38-dependent increases in the expression of matrix proteins such as collagen and fibronectin and αSMA. 11, 41, 42 Our in vitro assays place p38 downstream of extracellular signals such as TGFβ and AngII but upstream of known myofibroblast regulatory factors such as calcineurin, TRPC6, MK2, and SRF. 11, 21, 39, 40 The temporal-, lineage-, and injury-dependent activation of these combined molecular regulators will thus ultimately determine fibroblast function and hence the degree of fibrosis and its temporal persistence. However, our results are the first to define a fibroblast-specific role for MKK6-p38 signaling in vivo as an inducer of programmed myofibroblast differentiation and cardiac fibrosis.
The identification of a nodal role for p38 in transducing signals within the fibroblast suggests a pharmacologically tractable approach for antifibrotic therapies. Indeed, a number of well-characterized pharmacological inhibitors of p38 are available, some of which have already shown the ability to broadly blunt fibrotic remodeling in mouse models of heart, lung, and skeletal muscle disease. 16, 17, [43] [44] [45] Although such agents are clearly attractive to consider in treating human cardiac fibrotic disease states, we also need to consider the timing of antifibrotic therapies so that the initial wound healing phase can be effectively maintained. 
